Professor Raphael Breuer earned his MD from Tel Aviv University in 1975, completed Fellowships in Pulmonary Medicine at Boston University and then joined the Hadassah-Hebrew University Medical Center in 1985. He was named Professor of Medicine in 2007, Headed Pulmonary Medicine from 2006–2013, and currently Heads research in fibrotic lung disease. • Professor Breuer has led >40 clinical studies to assess the safety and efficacy of medications and devices. Under his leadership, Hadassah has participated in the great majority of international multicenter randomized trials of agents currently used for the treatment of asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, and idiopathic pulmonary fibrosis (IPF). His basic research focuses on elucidation of cellular and molecular mechanisms of IPF. In 2005, he brought molecular biologist Dr. Shulamit Wallach-Dayan to lead basic research; she is now the driving force behind research. They have shown that a complex mechanism of inflammatory cells and structural cells (epithelial, fibroblasts) apoptosize/proliferate, contributing to tissue remodeling. Resolution is mediated by T cells expressing FasL. Lung fibroblast accumulation is mediated by evasion from T cell-induced apoptosis, leading to unremitting collagen deposition; fibrosis may abate if the immune system is empowered to induce fibroblast apoptosis. Current research focuses on (1) mechanisms controlling apoptosis/proliferation in lung cells; (2) mechanisms governing lung immune-surveillance and their impact on fibrosis; (3) the effect of aging on mechanisms and resolution of lung fibrosis in a murine model and in humans; and (4) development of a humanized mouse model to assess physiological- vs. pathophysiological-lung fibrosis.